Table 1.
Drug delivery systems improving checkpoint blockade mAb delivery and therapy.
| Approach | Article | Drug Delivery System | Results |
|---|---|---|---|
| Microparticles for sustained mAb release | Lei et al. [58] | Silica microparticles | Funtionalizing mesoporous silica and modjtywig the pore sizes within the micropartides resulted in prolonged release mAb that improved antitumor immunity resulting from immunotherapy. |
| Rahimtan et al.[57] | Polymeric microparticles | Varying the polymer composition of micropartides influenced mAb release kinetics to enable tumor- localized sustained release over 30 days but resulted in comparable animal survival relative to a control formulation. | |
|
| |||
| Hyorogel for sustained mAb release | Li et al [36] | Alginate Hyorogel | Hyotogel-mediated sustained release of anti-PD-1 mAb into serum and retention in the tumor resulted in increased levels of CD4 and CD8 T cells while redudng regulatory Tcells in the spleen tumor draining lymph node, and tumor. |
|
| |||
| Microneedle (MN)- mediated sustained and local mAb release | Wang et al. 2016 [60] | Glucose triggered pH- reductions release mAb from MN-delivered nanopartides | MN administration of nanopartides encapsulating anti-PD-1 mAb improved anti-tumor immuraty via enhanced tumor retention of mAb causing local inflfration of CD8+ T cells as well as improved survival and tumor reduction |
| Ye et al. [59] | Hyaiuronidase triggered degradation of MN- delivered nanopartides | By improving the retention and sustained release of mAb within the tumor, a single administration of mAb loaded nanopartides via a MN patch improved anti-PD-1 mAb therapy, induoing enhanced tumor infiltration of CD8+ Tcells and prolonged animal survival | |
|
| |||
| Therapeutic mAb “hitehhidng” for tumor- targeted delivery | Wang et al. 2017 [64] | Platelet based Carrier | Decorating platelets with anti-PD-L1 mAb enabled its “hitchhikkig” to the tumor and triggered release following platelet actiesion with in tumors, resulting in enhanced accumulation of mAb with in the tumor and an increased CD8+to Treg ratio compared to i.v. administration which prolonged animal survival |